IR
IRTC.US iRhythm Technologies Inc
- Market cap
- USD 3.05B
- P/E
- -
- P/B
- 17.22x
- ROE
- -33.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IRTC.US undervalued?
Graham numberThe Graham number of iRhythm Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
iRhythm Technologies Inc fundamental analysis
No fundamental analysis for iRhythm Technologies Inc yet.
iRhythm Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About iRhythm Technologies Inc
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electro…
Full company profileiRhythm Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
iRhythm Technologies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 64.1M | 99.1M | 147M | 215M | 265M | 323M | 411M | 493M | 592M | 747M | 860M |
| Gross Profit | 43.2M | 70.9M | 108M | 162M | 195M | 214M | 282M | 332M | 408M | 527M | 625M |
| Operating Income | -15.6M | -27.6M | -45.7M | -54.8M | -43.7M | -99.9M | -114M | -125M | -116M | -36.8M | -62.6M |
| EBITDA | -17.1M | -24.8M | -45.0M | -49.4M | -29.2M | -83.2M | -92.1M | -96.9M | -74.1M | -3.97M | -20.2M |
| Net Income | -20.9M | -29.7M | -50.4M | -54.6M | -43.8M | -101M | -116M | -123M | -113M | -44.6M | -58.9M |
| EPS | -3.95 | -1.31 | -2.11 | -2.16 | -1.58 | -3.46 | -3.88 | -4.04 | -3.63 | -1.39 | -1.78 |
| Balance Sheet | |||||||||||
| Total Assets | 138M | 133M | 120M | 306M | 512M | 463M | 448M | 433M | 931M | 1.02B | 1.09B |
| Total Liabilities | 45.6M | 53.6M | 65.3M | 171M | 170M | 183M | 208M | 223M | 841M | 867M | 914M |
| Shareholders' Equity | 92.6M | 79.6M | 54.4M | 135M | 342M | 280M | 240M | 210M | 90.9M | 153M | 177M |
| Cash & Short-term Investments | 106M | 102M | 78.3M | 141M | 335M | 239M | 213M | 134M | 536M | 584M | 561M |
| Total Debt | 32.2M | 34.0M | 34.9M | 129M | 122M | 118M | 131M | 130M | 737M | 731M | 726M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -16.7M | -14.9M | -29.1M | -21.9M | -13.8M | -37.8M | -23.0M | -50.1M | 3.39M | 80.9M | 39.1M |
| Capital Expenditure | 2.76M | 3.56M | 5.18M | 20.5M | 13.6M | 28.1M | 29.8M | 40.4M | 48.9M | 46.3M | 48.6M |
| Free Cash Flow | -19.4M | -18.5M | -34.2M | -42.3M | -27.3M | -65.8M | -52.8M | -90.5M | -45.6M | 34.5M | -9.48M |
| Ratios | |||||||||||
| ROE | -22.6% | -37.4% | -92.6% | -40.3% | -12.8% | -36.3% | -48.4% | -58.7% | -124.6% | -29.2% | -33.2% |
| ROA | -15.1% | -22.3% | -42.1% | -17.8% | -8.6% | -21.9% | -25.9% | -28.5% | -12.2% | -4.4% | -5.4% |
| Net Profit Margin | -32.6% | -30.0% | -34.2% | -25.4% | -16.5% | -31.4% | -28.3% | -25.0% | -19.1% | -6.0% | -6.8% |
| Debt to Equity | 0.35x | 0.43x | 0.64x | 0.95x | 0.36x | 0.42x | 0.55x | 0.62x | 8.11x | 4.79x | 4.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
iRhythm Technologies Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 25.9M | 0.88 | - |
| 2020 | USD 10.0M | 0.36 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns iRhythm Technologies Inc
- Insiders 1.40%
- Institutions 98.61%
- Public & others 0.00%
- Shares outstanding 33.2M
- Free float 30.9M
Top funds holding IRTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.03M | 3.11% | +0.34% | Sep 2026 |
| iShares Russell 2000 ETF | 838K | 2.52% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 728K | 2.19% | -2.14% | Sep 2026 |
| Eventide Gilead N | 582K | 1.76% | +25.46% | Jun 2026 |
| Vanguard Explorer Inv | 522K | 1.57% | 0.00% | Sep 2026 |
| FullerThaler Behavioral Sm-Cp Gr R6 | 447K | 1.35% | +2.78% | Jun 2026 |
| Artisan Mid Cap Investor | 428K | 1.29% | +13.13% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 405K | 1.22% | -5.24% | Sep 2026 |
| Fidelity Small Cap Index | 362K | 1.09% | +0.17% | Aug 2026 |
| Harbor Small Cap Growth Instl | 332K | 1.00% | +133.76% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 310K | 0.94% | -0.38% | Oct 2026 |
| BNP Paribas Disrpt Tech Cl D | 289K | 0.87% | +11.36% | Sep 2026 |
| Fidelity Select Medical Tech and Devcs | 280K | 0.84% | 0.00% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 278K | 0.84% | 0.00% | Jun 2026 |
| BNP Paribas Health Cr Innovtr Cl Cap | 244K | 0.74% | +6.45% | Sep 2026 |
| Vanguard Strategic Equity Inv | 241K | 0.73% | +40.43% | Sep 2026 |
| BNP Paribas US Small Cap ClassicC | 241K | 0.73% | +8.81% | Sep 2026 |
| Bridge Builder Mid Cap Fund | 232K | 0.70% | -6.51% | Oct 2026 |
| American Funds SMALLCAP World A | 207K | 0.62% | -36.55% | Sep 2026 |
| Invesco Main Street Small Cap R6 | 196K | 0.59% | +479.37% | Sep 2026 |
Top institutions holding IRTC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.99M | 9.00% | +8.91% | Jun 2026 |
| RTW INVESTMENTS, LLC | 2.18M | 6.58% | +30.81% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.91M | 5.77% | +6.55% | Jun 2026 |
| Artisan Partners Limited Partnership | 1.66M | 5.00% | +14.43% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.46M | 4.41% | +1.21% | Jun 2026 |
| Millennium Management LLC | 1.41M | 4.24% | -12.53% | Jun 2026 |
| FMR Inc | 1.19M | 3.59% | -12.48% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 945K | 2.85% | -9.83% | Jun 2026 |
| Geode Capital Management, LLC | 882K | 2.66% | +7.93% | Jun 2026 |
| Eventide Asset Management, LLC | 880K | 2.65% | +15.71% | Jun 2026 |
| BNP Paribas Investment Partners SA | 867K | 2.61% | +13.71% | Jun 2026 |
| State Street Corp | 857K | 2.58% | +8.65% | Jun 2026 |
| Holocene Advisors, LP | 784K | 2.36% | -37.24% | Jun 2026 |
| JPMorgan Chase & Co | 766K | 2.31% | +7.18% | Jun 2026 |
| Stephens Inv Mgmt Group LLC | 693K | 2.09% | +23.49% | Jun 2026 |
| Fuller & Thaler Asset Management Inc | 685K | 2.07% | +1.60% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 675K | 2.04% | +133.78% | Sep 2026 |
| BRAIDWELL LP | 654K | 1.97% | +7.22% | Jun 2026 |
| D. E. Shaw & Co LP | 630K | 1.90% | +13.61% | Jun 2026 |
| Manufacturers Life Insurance Co | 561K | 1.69% | +43.70% | Jun 2026 |
iRhythm Technologies Inc company profile
- Company name
- iRhythm Technologies Inc
- Ticker
- IRTC.US
- Exchange
- USA Stocks
- Listed since
- Oct 20, 2016
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,400
- Fiscal year end
- December
- Address
- 699 8th Street, San Francisco, CA, United States, 94103
- Phone
- 415 632 5700
- Website
- irhythmtech.com
About iRhythm Technologies Inc
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
iRhythm Technologies Inc management
10- Mr. Quentin S. BlackfordPresident, CEO & Director · born 1979
- Mr. Daniel G. WilsonCFO & Principal Financial Officer · born 1982
- Dr. Minang P. Turakhia M.D., M.S.Chief Medical & Scientific Officer and Executive VP of Advanced Technologies · born 1974
- Mr. Patrick Michael Murphy J.D.Chief Business & Legal Officer · born 1979
- Mr. Chad M. PattersonChief Commercial and Product Officer · born 1982
- Mr. Mervin SmithExecutive Vice President of Business Operations · born 1975
- Mr. Marc RosenbaumSenior VP of Finance & Chief Accounting Officer · born 1973
- Mr. Brian LawrenceExecutive VP & CTO · born 1970
- Ms. Lisa PecoraSenior Vice President of Finance & Investor Relations
- Mr. Sean Clinton FreemanExecutive Vice President of Strategy & Corporate Development · born 1976